DexCom (DXCM) Tops Q3 EPS by 16c; offers guidance

DexCom (NASDAQ: DXCM) reported Q3 EPS of $0.50, $0.16 better than the analyst estimate of $0.34. Revenue for the quarter came in at $975 million versus the consensus estimate of $939.19 million.

GUIDANCE:

DexCom sees FY2023 revenue of $3.575-3.6 million, versus the consensus of $3.539 million.

For earnings history and earnings-related data on DexCom (DXCM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c